Treatment will become even more important
These results could prompt more targeted drugs for the disease, offering further relief to those with Hodgkin lymphoma. However, of course, nothing is yet entirely conclusive or impervious to faults.
Dr. Alasdair Rankin, Director of Research at Bloodwise explains both the benefits and potential downfalls: "Because of research, treatments for many people with Hodgkin lymphoma are now good, and around 80 percent of all people affected survive in the long-term. Although this is good news, treatments can have long-term health effects, such as infertility and secondary cancers, so finding kinder treatments for Hodgkin lymphoma is important. We welcome this study, which sheds new light on how Hodgkin lymphoma develops."